Geraldine Harriman

Geraldine Harriman, Ph.D., is Co-Founder and Chief Scientific Officer at HotSpot Therapeutics, a biotechnology company developing first-in-class allosteric therapies by applying HotSpot’s Smart Allostery platform. Prior to co-founding HotSpot, she served as Vice President at Nimbus Therapeutics, where she led the effort to discover Firsocostat, a leading drug for NASH. She also served as Vice President of Galenea, co-led the inflammation therapeutic area at Millennium Pharmaceuticals, and was a founding member of the scientific team at LeukoSite. Geraldine received her Ph.D. in chemistry at the University of Rhode Island and completed her postdoctoral fellowship at the University of Kansas.